POC testing enables the healthcare experts to diagnose a patient in the physician’s office, in an ambulance, at home, in the hospital and field. The microfluidic technology-assisted devices are being engaged for POC testing, as they demand small volumes of samples and utilize the micro-fabricated channels to analyze such samples. POC testing devices are already prominent in the blood, glucose, HIV testing domains and hemoglobin. The future POC testing devices are probable to aim more on the antibiotics therapies and cancer.
Along the broad variety of benefits suggested by such these devices, microfluidic technology-based POC testing devices have an enormous potential in the underdeveloped and developed regions, as the percentage of the populace affected by such disease is great.
According to the report analysis, ‘Global Microfluidics Market (By Product type- Reagents, Microfluidic Chips, Micropumps, Microfluidic Sensors, and Others. By Material- Glass, Polymer, Silicon, and Other Materials. By Application- Peripheral Vascular Disorder, Wound Care Management, Point-of Care Testing, Proteomic Analysis, Drug Delivery,and Others)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017 – 2025’ states that in the worldwide microfluidics market there are numerous players which presently operating in this market more actively for leading the fastest market growth and dominating the effective value of market share around the globe throughout the short span of time while increasing the applications of such, decreasing the cost, spreading the awareness related to such and studying the government regulations more actively comprises Agilent Technologies, Inc., Abbott Laboratorie, Bausch + Lomb, Bio-Rad Laboratories, Becton, Dickinson and Company, Danaher Corporation, F. Hoffmann-La Roche AG, Micronit Micro Technologies B.V., Therma Fisher Scientific and several others.
Vigorous advancement of diagnostic devices in the past numerous years have yielded the requirement for the microfluidics market. Not only has this, the effective growth in the applications in the fields of drug delivery, pharmaceutical industries are another prime factor propelling the market demand. In addition, aids such as accuracy, liability, decreased costs along with other advantages are the most important aspects which have augmented the requirement of this market.
The impending of this technology has concerned both industry and academia to familiarize newer techniques of sample identification and technologies that can bring down mechanical blunders. According to the Florida Atlantic University, stimulated by the pregnancy test, the scientists have advanced a novel method to store the microfluidic devices without refrigeration for months allowing underdeveloped nations to approve a reliable and reasonable way to treat patients.
The prospective of this technology is fascinating numerous players to enlarge their market share through associations. Collaborations with other market professionals allow development of strong product portfolios and fresher and improved versions of microfluidic devices/technology.
In addition, the biochemical variations in the patient’s blood can indicate the organ damage or dysfunction, previous to observable microscopic cellular indemnities or several other symptoms. So there has been a great requirement for the development of an easy-to-handle and reasonable clinical diagnostic biochip utilizing the fully integrated plastic microfluidic chips, which have the specimen/identifying ability of fast and consistent measurements of metabolic parameters from an individual with the smallest invasion. Thus, the increment in the clinical diagnostics is predicted to propel the market’s growth. Therefore, in the coming years, it is anticipated that the market of microfluidics will increase around the globe more significantly over the near future.
For more information on the research report, refer to below link:-
Ankur Gupta, Head Marketing & Communications